Comparison of different Aspirin in diabetic patients.

Comparison of anti-platelet efficacy of four different marketed formulations of Aspirin in diabetic patients.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/09/009673

Enrollment

120

Registered

2017-09-06

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients with Type 2 DM receiving oral anti-diabetic and who have two or more risk factors for cardiovascular disease

Interventions

Intervention1: Acetyl salicylic acid 150mg plain: Plain Acetyl salicylic acid 150mg Frequency: once a day at morning on empty stomach. Route of Administration: Oral Total duration of therapy: 14 Days

Eligibility

Inclusion criteria

Inclusion criteria: Patients with Type 2 DM receiving oral anti-diabetic with dietary modifications and who have two or more risk factors for cardiovascular disease.

Exclusion criteria

Exclusion criteria: Patients having age Uncontrolled diabetes mellitus (Fasting BSL > 300 mg/dL Despite therapy) Uncontrolled Hypertension Abnormal Liver Function Tests and/or Renal Function Tests. Patients receiving any form or dose of Aspirin therapy for >7 days Patient receiving any other antithrombotic or anti-coagulant therapy. Patients having deranged bleeding and/ or clotting time at baseline study. Patient on insulin.

Design outcomes

Primary

Measure	Time frame
ADP induced platelet aggregationTimepoint: Day 0 Day 15	—

Secondary

Measure	Time frame
Bleeding Time Steady state plasma salicylate concentrationTimepoint: Day 0 Day 15	—

Countries

India

Contacts

Public ContactKANHARAM NARAYAN PATEL

B. J. Govt. Medical College and Sassoon Gen. Hospital

daswani_bharti@rediffmail.com9421965337

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026